Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28972632 | 0.71 | CA1 (0.31) | CA1CA9 | |
| SCHEMBL3014139 | 0.69 | HTT (0.31) | CA1CA9 | |
| SCHEMBL160028 | 0.68 | CA1 (0.34) | CA1CA9 | |
| SCHEMBL1501891 | 0.68 | CA1 (0.32) | CA1CA9 | |
| SCHEMBL3605917 | 0.68 | CA1 (0.32) | CA1CA9 | |
| SCHEMBL28412569 | 0.67 | CYP1A2 (0.37) | — | |
| SCHEMBL30023511 | 0.67 | CYP1A2 (0.34) | — | |
| SCHEMBL3012197 | 0.66 | — | — | |
| SCHEMBL29955980 | 0.66 | — | — | |
| SCHEMBL218307 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161353-A | Design, synthesis and activity evaluation of pyranopyrimidine heterocyclic p97/VCP inhibitors | 首都医科大学 | 2024-12-20 | — | — | CN | claimed |
| EP-1663993-B1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-12 | — | — | EP | claimed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | claimed |
| EP-4671252-A4 | HETEROCYCLIC-SUBSTITUTED PYRIMIDOPYRAN COMPOUND AND USE THEREOF | D3 BIO WUXI CO LTD (CN) | 2026-05-27 | — | — | EP | disclosed |
| CN-116761799-B | Pyrimidopyran compounds | 德昇济医药(无锡)有限公司 | 2026-03-06 | — | — | CN | disclosed |
| CN-116761799-B | Pyrimidopyran compounds | 德昇济医药(无锡)有限公司 | 2026-03-06 | — | — | CN | disclosed |
| WO-2026046397-A1 | HETEROCYCLIC SUBSTITUTED PYRIMIDOPYRAN COMPOUNDS AND USES THEREOF | D3 BIO (WUXI) CO., LTD. (CN) | 2026-03-05 | — | — | WO | disclosed |
| WO-2026046397-A1 | HETEROCYCLIC SUBSTITUTED PYRIMIDOPYRAN COMPOUNDS AND USES THEREOF | D3 BIO (WUXI) CO., LTD. (CN) | 2026-03-05 | — | — | WO | disclosed |
| EP-4671252-A1 | HETEROCYCLIC-SUBSTITUTED PYRIMIDOPYRAN COMPOUND AND USE THEREOF | D3 Bio(Wuxi) Co., Ltd. (CN) | 2025-12-31 | — | — | EP | disclosed |
| WO-2025195335-A1 | HETEROCYCLIC SUBSTITUTED PYRIMIDOPYRAN COMPOUNDS AND THEIR APPLICATIONS | D3 BIO (WUXI) CO., LTD. (CN) | 2025-09-25 | — | — | WO | disclosed |
| WO-2025195335-A1 | HETEROCYCLIC SUBSTITUTED PYRIMIDOPYRAN COMPOUNDS AND THEIR APPLICATIONS | D3 BIO (WUXI) CO., LTD. (CN) | 2025-09-25 | — | — | WO | disclosed |
| WO-2009047514-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| EP-1663993-B1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
| US-6448256-B1 | PRECURSORS OF N-SUBSTITUTED DERIVATIVES OF 6-AMINOURACILS, 6-AMINOISOCYTOSINES, GUANINES AND 2-AMINOADENINES HAVING A CLEAVABLE ESTER GROUP; GREATER WATER SOLUBILITY AND ORAL BIOAVAILABILITY; TREATING GRAM POSITIVE BACTERIAL INFECTIONS | UNIVERSITY OF MASSACHUSETTS | 2002-09-10 | — | — | US | disclosed |
| EP-1185517-A1 | ANTIBIOTIC PRODRUGS | University of Massachusetts (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000071523-A1 | ANTIBIOTIC PRODRUGS | UNIVERSITY OF MASSACHUSETTS (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-1022278-A1 | TETRACYCLICAL DERIVATIVES FROM PYRIMIDINE | Ashkinazi, Rimma Iliinichna (RU) | 2000-07-26 | — | — | EP | disclosed |
| US-6071905-A | TREATING TUBERCULOSIS, MYCOBACTERIOSIS, VIRAL AND IMMUNE DISEASES, CHLAMYDIA INFECTIONS, ANTITUMOR AND -CARCINOGENIC AGENTS; MICROBIOCIDES, IN PARTICULAR TO MYCOBACTERIA RESISTANT TO ISONIAZIDE; STIMULANTES INTERFERONS | NATURAL DRUG SCIENCES, LLC (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0276057-A2 | Piperazinylpyrimidines as beta-adrenergic receptor blocking agents | MERCK & CO. INC. (US) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123510-A1 | Guanidine derivatives | NPFFR1, NPFFR2, OGFR | CA1 4362/4885CA9 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.